IGC Pharma, Inc. (IGC)
NYSEAMERICAN: IGC · Real-Time Price · USD
0.2799
-0.0050 (-1.76%)
Oct 9, 2026, 4:00 PM EDT - Market closed
IGC Pharma Cash Flow Statement
Financials in millions USD. Fiscal year is April - March.
Millions USD. Fiscal year is Apr - Mar.
Operating Activities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 |
Net Income | -6.45 | -7.12 | -13 | -11.51 | -15.02 | -8.81 |
Depreciation & Amortization | 0.57 | 0.62 | 0.64 | 0.66 | 0.65 | 0.48 |
Loss (Gain) From Sale of Assets | -0.03 | -0.03 | -0.04 | 0.04 | - | - |
Asset Writedown & Restructuring Costs | 0.15 | 0.15 | 3.45 | - | 0.83 | - |
Loss (Gain) From Sale of Investments | - | - | - | - | 0.05 | 0.17 |
Stock-Based Compensation | 2.02 | 1.64 | 1.77 | 2.84 | 2.2 | 0.66 |
Provision & Write-off of Bad Debts | 0.01 | 0.01 | 0.09 | 0.13 | 1.72 | - |
Other Operating Activities | -1.07 | - | - | - | -0.43 | - |
Change in Accounts Receivable | -0.01 | -0.01 | -0.03 | 0.01 | 0.05 | -0.04 |
Change in Inventory | 0.17 | 0.18 | 1.01 | 0.9 | 1.93 | -1.23 |
Change in Accounts Payable | -0.14 | 0.11 | 0.24 | -0.45 | 0.5 | -0.29 |
Change in Other Net Operating Assets | -0.78 | -0.35 | 0.67 | 0.34 | 0.05 | -1.73 |
Operating Cash Flow | -5.54 | -4.8 | -5.2 | -7.05 | -7.46 | -10.8 |
Operating Cash Flow Growth | - | - | - | - | - | - |
Investing Activities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 |
Capital Expenditures | -0.08 | -0.11 | -0.14 | -0.31 | -0.24 | -1.47 |
Sale of Property, Plant & Equipment | 0.7 | 0.04 | 0.04 | 0.54 | 0.03 | - |
Sale (Purchase) of Intangibles | -0.64 | -0.37 | -0.38 | -0.31 | -0.54 | -0.12 |
Investment in Securities | -0.03 | - | 0.15 | -0.15 | - | 4.98 |
Investing Cash Flow | -0.04 | -0.44 | -0.32 | -0.24 | -0.74 | 3.39 |
Financing Activities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 |
Long-Term Debt Issued | - | - | - | - | - | 0.53 |
Total Debt Issued | - | - | - | - | - | 0.53 |
Long-Term Debt Repaid | - | -0 | -0 | -0 | -0 | - |
Total Debt Repaid | -0 | -0 | -0 | -0 | -0 | - |
Net Debt Issued (Repaid) | -0 | -0 | -0 | -0 | -0 | 0.53 |
Issuance of Common Stock | 5.11 | 4.45 | 3.53 | 0.1 | 4.14 | 14.16 |
Financing Cash Flow | 5.11 | 4.45 | 3.52 | 0.1 | 4.14 | 14.69 |
Net Cash Flow
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 |
Foreign Exchange Rate Adjustments | 0.03 | -0.01 | -0.01 | -0.08 | -0.03 | 0.02 |
Net Cash Flow | -0.44 | -0.79 | -2 | -7.26 | -4.09 | 7.29 |
Free Cash Flow
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 |
Free Cash Flow | -5.63 | -4.91 | -5.34 | -7.36 | -7.7 | -12.27 |
Free Cash Flow Growth | - | - | - | - | - | - |
Free Cash Flow Margin | -508.68% | -386.07% | -396.80% | -807.57% | -1939.04% | -1366.37% |
Free Cash Flow Per Share | -0.07 | -0.06 | -0.09 | -0.14 | -0.15 | -0.29 |
Levered Free Cash Flow | -2.52 | -2.91 | -3.17 | -3.37 | -2.47 | -9.21 |
Unlevered Free Cash Flow | -2.52 | -2.91 | -3.17 | -3.37 | -2.47 | -9.21 |